• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Arcadia Biosciences Inc. (Amendment)

    2/11/22 8:04:22 AM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples
    Get the next $RKDA alert in real time by email
    SC 13G/A 1 ea155281-13ga4intra_arcadia.htm AMENDMENT NO. 4 TO SCHEDULE 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 4)*

     

    Arcadia Biosciences, Inc.

     

    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

     

    (Title of Class of Securities)

     

    039014204

     

    (CUSIP Number)

     

    December 31, 2021

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    a.☐ Rule 13d-1(b)
    b.☒ Rule 13d-1(c)
    c.☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    Page 1 of 6 

     

      

    CUSIP No. 039014204  

     

    1. Names of Reporting Persons.
       
      Mitchell P. Kopin
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ☐
      (b) ☐
    3. SEC Use Only
         
    4. Citizenship or Place of Organization United States of America
         

    Number of

    Shares Beneficially

    Owned by Each

    Reporting

    Person With:

    5. Sole Voting Power 0
         
    6. Shared Voting Power 1,058,559
         
    7. Sole Dispositive Power 0
         
    8. Shared Dispositive Power 1,058,559
           
    9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,058,559 (see Item 4)
         
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
         
    11. Percent of Class Represented by Amount in Row (9) 4.6% (see Item 4)
         
    12. Type of Reporting Person (See Instructions)  
         
      IN; HC  

      

    Page 2 of 6 

     

      

    CUSIP No. 039014204  

     

    1. Names of Reporting Persons.
       
      Daniel B. Asher
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ☐
      (b) ☐
    3. SEC Use Only
         
    4. Citizenship or Place of Organization United States of America
         

    Number of

    Shares Beneficially

    Owned by Each

    Reporting

    Person With:

    5. Sole Voting Power 0
         
    6. Shared Voting Power 1,058,559
         
    7. Sole Dispositive Power 0
         
    8. Shared Dispositive Power 1,058,559
           
    9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,058,559 (see Item 4)
         
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
         
    11. Percent of Class Represented by Amount in Row (9) 4.6% (see Item 4)
         
    12. Type of Reporting Person (See Instructions)  
         
      IN; HC  

      

    Page 3 of 6 

     

     

    CUSIP No. 039014204  

     

    1. Names of Reporting Persons.
       
      Intracoastal Capital LLC
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ☐
      (b) ☐
    3. SEC Use Only
         
    4. Citizenship or Place of Organization Delaware
         

    Number of

    Shares Beneficially

    Owned by Each

    Reporting

    Person With:

    5. Sole Voting Power 0
         
    6. Shared Voting Power 1,058,559
         
    7. Sole Dispositive Power 0
         
    8. Shared Dispositive Power 1,058,559
           
    9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,058,559 (see Item 4)
         
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
         
    11. Percent of Class Represented by Amount in Row (9) 4.6% (see Item 4)
         
    12. Type of Reporting Person (See Instructions)  
         
      OO  

      

    Page 4 of 6 

     

      

    This Amendment No. 4 is being filed jointly by the Reporting Persons and amends the Schedule 13G initially filed by the Reporting Persons with the Securities and Exchange Commission (the “SEC”) on June 21, 2018, as amended by Amendment No. 1 filed by the Reporting Persons with the SEC on February 8, 2019 as amended by Amendment No. 2 filed by the Reporting Persons with the SEC on February 11, 2020 and as amended by Amendment No. 3 thereto filed by the Reporting Persons with the SEC on January 29, 2021 (collectively, the “Schedule 13G”).

     

    Except as set forth below, all Items of the Schedule 13G remain unchanged. All capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13G.

     

    Item 4. Ownership.

     

    (a) and (b):

     

    As of close of business on December 31, 2021, each of the Reporting Persons may have been deemed to have beneficial ownership of 1,058,559 shares of Common Stock, which consisted of (i) 372,950 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal (“Intracoastal Warrant 1”), (ii) 252,915 shares of Common Stock issuable upon exercise of a second warrant held by Intracoastal (“Intracoastal Warrant 2”), (iii) 119,459 shares of Common Stock issuable upon exercise of a third warrant held by Intracoastal (“Intracoastal Warrant 3”) and (iv) 313,235 shares of Common Stock issuable upon exercise of a fourth warrant held by Intracoastal (“Intracoastal Warrant 4”), and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 4.6% of the Common Stock, based on (1) 22,184,235 shares of Common Stock outstanding as of November 8, 2021 as reported by the Issuer, plus (2) 372,950 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1, (3) 252,915 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2, (4) 119,459 shares of Common Stock issuable upon exercise of Intracoastal Warrant 3 and (5) 313,235 shares of Common Stock issuable upon exercise of Intracoastal Warrant 4.

     

    (c) Number of shares as to which each Reporting Person has:

     

    (i) Sole power to vote or to direct the vote: 0.

     

    (ii) Shared power to vote or to direct the vote: 1,058,559.

     

    (iii) Sole power to dispose or to direct the disposition of  0.

     

    (iv) Shared power to dispose or to direct the disposition of 1,058,559.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following þ.

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    Page 5 of 6 

     

      

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 11, 2022

     

      /s/ Mitchell P. Kopin
      Mitchell P. Kopin
       
      /s/ Daniel B. Asher
      Daniel B. Asher
       
      Intracoastal Capital LLC
       
      By: /s/ Mitchell P. Kopin
        Mitchell P. Kopin, Manager

     

     

     Page 6 of 6

     

    Get the next $RKDA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RKDA

    DatePrice TargetRatingAnalyst
    1/3/2022$7.00 → $6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $RKDA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Arcadia Biosciences (RKDA) Announces First Quarter 2025 Financial Results and Business Highlights

      -- Revenues increase 22% year over year driven by 90% growth in Zola® ---- Arcadia sells patents for $750K and eliminates $1M in liabilities ---- Roosevelt agreement amended to provide greater certainty regarding exchange ratio -- DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the first quarter of 2025. The company has scheduled a conference call at 2:00 p.m. Eastern time (11:00 a.m. Pacific time) to discuss first-quarter results and key strategic achievements. "The momentum we experienced in the second half of 2024 has

      5/8/25 8:02:00 AM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • Arcadia Biosciences (RKDA) Announces Date of First Quarter 2025 Financial Results and Business Highlights Conference Call

      DALLAS, April 29, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, today announced that it will release its financial and business results for the first quarter of 2025 on May 8, 2025. The company has scheduled a conference call for 2:00 p.m. Eastern time (11:00 a.m. Pacific time) to discuss first-quarter results and key strategic achievements. Interested participants can join the conference call using the following options: An audio-only webcast of the conference call will be available, with a link posted in the Investors section of Arcadia's website.To join the live call, please register

      4/29/25 8:02:00 AM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2024 Financial Results and Business Highlights

      -- Year-over-year revenues grew 56% in Q4 and 13% for full year -- -- Zola® year-over-year revenues increased 124% in Q4 and 46% for full year -- -- Company plans business combination with Roosevelt Resources, Inc. -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the fourth quarter and full year of 2024. "We are extremely pleased with the progress we made in 2024, particularly in the second half of the year following the sale of our GoodWheat™ assets," said T.J. Schaefer, president and CEO. "Our focus on Zola® coconut water led to 80 percent revenue growth f

      3/20/25 4:05:00 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples

    $RKDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Kawakami Mark bought $1,743 worth of shares (700 units at $2.49), increasing direct ownership by 35% to 2,681 units (SEC Form 4)

      4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)

      2/5/25 7:34:41 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • Chief Executive Officer Schaefer Thomas J. bought $1,743 worth of shares (700 units at $2.49), increasing direct ownership by 33% to 2,819 units (SEC Form 4)

      4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)

      2/5/25 7:24:18 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • Chief Financial Officer Kawakami Mark bought $1,442 worth of shares (700 units at $2.06), increasing direct ownership by 55% to 1,981 units (SEC Form 4)

      4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)

      8/20/24 8:11:11 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples

    $RKDA
    SEC Filings

    See more
    • Arcadia Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Arcadia Biosciences, Inc. (0001469443) (Filer)

      5/16/25 5:21:37 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • SEC Form 10-Q filed by Arcadia Biosciences Inc.

      10-Q - Arcadia Biosciences, Inc. (0001469443) (Filer)

      5/8/25 8:07:59 AM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • SEC Form 425 filed by Arcadia Biosciences Inc.

      425 - Arcadia Biosciences, Inc. (0001469443) (Subject)

      5/8/25 8:06:33 AM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples

    $RKDA
    Financials

    Live finance-specific insights

    See more

    $RKDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $RKDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $RKDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Arcadia Biosciences (RKDA) Announces First Quarter 2025 Financial Results and Business Highlights

      -- Revenues increase 22% year over year driven by 90% growth in Zola® ---- Arcadia sells patents for $750K and eliminates $1M in liabilities ---- Roosevelt agreement amended to provide greater certainty regarding exchange ratio -- DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the first quarter of 2025. The company has scheduled a conference call at 2:00 p.m. Eastern time (11:00 a.m. Pacific time) to discuss first-quarter results and key strategic achievements. "The momentum we experienced in the second half of 2024 has

      5/8/25 8:02:00 AM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • Arcadia Biosciences (RKDA) Announces Date of First Quarter 2025 Financial Results and Business Highlights Conference Call

      DALLAS, April 29, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, today announced that it will release its financial and business results for the first quarter of 2025 on May 8, 2025. The company has scheduled a conference call for 2:00 p.m. Eastern time (11:00 a.m. Pacific time) to discuss first-quarter results and key strategic achievements. Interested participants can join the conference call using the following options: An audio-only webcast of the conference call will be available, with a link posted in the Investors section of Arcadia's website.To join the live call, please register

      4/29/25 8:02:00 AM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2024 Financial Results and Business Highlights

      -- Year-over-year revenues grew 56% in Q4 and 13% for full year -- -- Zola® year-over-year revenues increased 124% in Q4 and 46% for full year -- -- Company plans business combination with Roosevelt Resources, Inc. -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the fourth quarter and full year of 2024. "We are extremely pleased with the progress we made in 2024, particularly in the second half of the year following the sale of our GoodWheat™ assets," said T.J. Schaefer, president and CEO. "Our focus on Zola® coconut water led to 80 percent revenue growth f

      3/20/25 4:05:00 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • SEC Form 4 filed by Chief Financial Officer Kawakami Mark

      4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)

      5/12/25 8:56:01 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • SEC Form 4 filed by Chief Executive Officer Schaefer Thomas J.

      4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)

      5/12/25 8:48:31 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • Chief Financial Officer Kawakami Mark bought $1,743 worth of shares (700 units at $2.49), increasing direct ownership by 35% to 2,681 units (SEC Form 4)

      4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)

      2/5/25 7:34:41 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • HC Wainwright & Co. reiterated coverage on Arcadia Biosciences with a new price target

      HC Wainwright & Co. reiterated coverage of Arcadia Biosciences with a rating of Buy and set a new price target of $6.00 from $7.00 previously

      1/3/22 6:06:17 AM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • HC Wainwright & Co. reiterated coverage on Arcadia Biosciences with a new price target

      HC Wainwright & Co. reiterated coverage of Arcadia Biosciences with a rating of Buy and set a new price target of $7.00 from $6.00 previously

      6/1/21 6:50:30 AM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • Lake Street initiated coverage on Arcadia Biosciences with a new price target

      Lake Street initiated coverage of Arcadia Biosciences with a rating of Buy and set a new price target of $4.50

      5/11/21 12:00:10 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • SEC Form SC 13G/A filed by Arcadia Biosciences Inc. (Amendment)

      SC 13G/A - Arcadia Biosciences, Inc. (0001469443) (Subject)

      2/14/24 2:55:48 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • SEC Form SC 13G filed by Arcadia Biosciences Inc.

      SC 13G - Arcadia Biosciences, Inc. (0001469443) (Subject)

      1/3/24 12:26:00 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • SEC Form SC 13G filed by Arcadia Biosciences Inc.

      SC 13G - Arcadia Biosciences, Inc. (0001469443) (Subject)

      2/14/23 1:22:05 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples

    $RKDA
    Leadership Updates

    Live Leadership Updates

    See more
    • Arcadia Biosciences (RKDA) Announces Leadership Transition

      -- CEO Stan Jacot replaced by CFO Thomas J. Schaefer -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced that CEO Stan Jacot has left the company and been replaced by Thomas J. Schaefer, effective July 5, 2024. Schaefer was previously Arcadia's chief financial officer and will be replaced in that role by Mark Kawakami, Arcadia's current vice president of finance. "On behalf of Arcadia, I would like to thank Stan for his many contributions to the company," said Board of Directors Chairman Kevin Comcowich. "Under his leadership, Arcadia expanded the GoodWheat brand into three categories, sold the brand to

      7/9/24 8:02:00 AM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • Arcadia Biosciences (RKDA) Appoints Kevin Comcowich to Interim CEO

      DAVIS, Calif., Dec. 20, 2021 /PRNewswire/ -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced it has appointed Kevin Comcowich, current Chairman of the Arcadia Board of Directors, as interim chief executive officer, effective January 1, 2022, as the board of directors finalizes its search for a permanent CEO. As previously announced on September 7, 2021, the board of directors launched a national search for a new CEO as the company further expands into the consumer packaged goods (CPG) sector.

      12/20/21 10:55:00 AM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • Arcadia Biosciences (RKDA) Appoints Seasoned CPG Sales Executive Brian Schaffer to Senior Vice President of Sales

      DAVIS, Calif., Nov. 22, 2021 /PRNewswire/ --  Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced it has named Brian Schaffer as senior vice president of sales, as the company continues to expand its consumer goods platforms. A seasoned sales and general management executive with deep CPG experience, Schaffer has a proven track record of building and leading world class sales organizations. He is tasked with driving the retail launch of Arcadia's GoodWheat brand, a company priority in 2022 as it w

      11/22/21 8:00:00 AM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples